Answers are grounded in this paper and cite their sources.
The current intramuscular SARS-CoV-2 vaccine failed to prevent variant strain outbreaks due to its inadequate stimulation of mucosal immunity. Therefore, nasal immunization is emerging as a promising alternative approach. In the present research, we have effectively created a mucosal vaccine candidate, designated rLP18:S1, which is intended to express the S1 protein of the Omicron variant (B.1.1.529). By inserting lipid-anchored signal peptide sequences, it efficiently displayed the Omicron S1 protein on the surface of Lactiplantibacillus plantarum . Notably, the recombinant protein from rLP18:S1 exhibits superior antigenicity and stability. We immunized mice nasally with rLP18:S1, inducing a robust antigen-specific mucosal immune response against Omicron virus infection. These results hold promise for the preclinical and clinical development of the Omicron SARS-CoV-2 vaccine. • Successful development of a mucosal vaccine against the Omicron variant of SARS-CoV-2. • Efficient display of Omicron S1 protein on Lactiplantibacillus plantarum . • Intranasal rLP18:S1 vaccination-induced immune response against Omicron virus.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: